These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30133440)

  • 1. Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin.
    Khadir F; Shaler CR; Oryan A; Rudak PT; Mazzuca DM; Taheri T; Dikeakos JD; Haeryfar SMM; Rafati S
    PLoS Negl Trop Dis; 2018 Aug; 12(8):e0006701. PubMed ID: 30133440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antileishmanial effect of rapamycin as an alternative approach to control Leishmania tropica infection.
    Khadir F; Taheri T; Habibzadeh S; Zahedifard F; Gholami E; Heidari-Kharaji M; Oryan A; Rafati S
    Vet Parasitol; 2019 Dec; 276():108976. PubMed ID: 31739256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian Target of Rapamycin Inhibition in
    Rojas Márquez JD; Ana Y; Baigorrí RE; Stempin CC; Cerban FM
    Front Immunol; 2018; 9():313. PubMed ID: 29515594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
    Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
    Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against Leishmania species that cause tegumentary and visceral leishmaniasis.
    Sousa JKT; Antinarelli LMR; Mendonça DVC; Lage DP; Tavares GSV; Dias DS; Ribeiro PAF; Ludolf F; Coelho VTS; Oliveira-da-Silva JA; Perin L; Oliveira BA; Alvarenga DF; Chávez-Fumagalli MA; Brandão GC; Nobre V; Pereira GR; Coimbra ES; Coelho EAF
    Parasitol Int; 2019 Dec; 73():101966. PubMed ID: 31362122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.
    Dormond-Meuwly A; Roulin D; Dufour M; Benoit M; Demartines N; Dormond O
    Biochem Biophys Res Commun; 2011 Apr; 407(4):714-9. PubMed ID: 21439267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin attenuates Tc1 and Tc17 cell responses in cigarette smoke-induced emphysema in mice.
    Zhang H; Zhou X; Chen X; Lin Y; Qiu S; Zhao Y; Tang Q; Liang Y; Zhong X
    Inflamm Res; 2019 Nov; 68(11):957-968. PubMed ID: 31468083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species.
    Lage DP; Martins VT; Duarte MC; Costa LE; Tavares GSV; Ramos FF; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CAP; Coelho EAF
    Acta Trop; 2016 Jun; 158():220-230. PubMed ID: 26976272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The leishmanicidal activity of oleuropein is selectively regulated through inflammation- and oxidative stress-related genes.
    Kyriazis ID; Koutsoni OS; Aligiannis N; Karampetsou K; Skaltsounis AL; Dotsika E
    Parasit Vectors; 2016 Aug; 9(1):441. PubMed ID: 27501956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism.
    Vogel KR; Ainslie GR; Gibson KM
    J Inherit Metab Dis; 2016 Nov; 39(6):877-886. PubMed ID: 27518770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice.
    Abdossamadi Z; Seyed N; Zahedifard F; Taheri T; Taslimi Y; Montakhab-Yeganeh H; Badirzadeh A; Vasei M; Gharibzadeh S; Rafati S
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006123. PubMed ID: 29253854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan.
    Halliday A; Bates PA; Chance ML; Taylor MJ
    Parasit Vectors; 2016 Oct; 9(1):532. PubMed ID: 27716391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
    Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW
    J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo antileishmanial efficacy of a naphthoquinone derivate incorporated into a Pluronic
    Mendonça DVC; Tavares GSV; Lage DP; Soyer TG; Carvalho LM; Dias DS; Ribeiro PAF; Ottoni FM; Antinarelli LMR; Vale DL; Ludolf F; Duarte MC; Coimbra ES; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Barichello JM; Alves RJ; Coelho EAF
    Biomed Pharmacother; 2019 Jan; 109():779-787. PubMed ID: 30551531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice model.
    Heidari-Kharaji M; Taheri T; Doroud D; Habibzadeh S; Rafati S
    Appl Microbiol Biotechnol; 2016 Aug; 100(16):7051-60. PubMed ID: 26960322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin Ameliorates Experimental Autoimmune Encephalomyelitis by Suppressing the mTOR-STAT3 Pathway.
    Hou H; Miao J; Cao R; Han M; Sun Y; Liu X; Guo L
    Neurochem Res; 2017 Oct; 42(10):2831-2840. PubMed ID: 28600752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic Potential of Eugenol Emulsion in Experimental Visceral Leishmaniasis.
    Islamuddin M; Chouhan G; Want MY; Ozbak HA; Hemeg HA; Afrin F
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005011. PubMed ID: 27776125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A recombinant fusion protein displaying murine and human MHC class I- and II-specific epitopes protects against Leishmania amazonensis infection.
    Martins VT; Lage DP; Duarte MC; Carvalho AM; Costa LE; Mendes TA; Vale DL; Menezes-Souza D; Roatt BM; Tavares CA; Soto M; Coelho EA
    Cell Immunol; 2017 Mar; 313():32-42. PubMed ID: 28049560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model.
    Heidari-Kharaji M; Taheri T; Doroud D; Habibzadeh S; Badirzadeh A; Rafati S
    Parasite Immunol; 2016 Oct; 38(10):599-608. PubMed ID: 27213964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.